GlobeNewswire PharmaOriginal article
Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026
ConferenceDarlifarnibCabozantinibPositive
AI Analysis
Summary
Kura Oncology will present clinical data on darlifarnib combined with cabozantinib in cabozantinib-pretreated clear cell renal cell carcinoma patients at IKCS Europe 2026, building on prior ESMO 2025 findings regarding the combination's potential to overcome resistance.
Clinical Trial Data
Outcome Details
Data presentation on darlifarnib plus cabozantinib combination in cabozantinib-pretreated patients
Importance:5/10
Sentiment:
0.60
oncologycombination therapyresistance overcomeconference presentationrenal cell carcinoma
Related Companies
Read the original article
Published by GlobeNewswire Pharma on April 9, 2026 11:30 AM